DSIP Peptide Dosage in the Research Literature — DSIP Research
DSIP Peptide Dosage in the Research Literature
DSIP peptide dosage in published research varies substantially by species, route, and study objective. The primary human clinical trial dose is 25 nmol/kg administered intravenously — used in the Bes et al. (1992) matched-pairs insomnia study (n=16) and the Dick et al. (1983, 1984) withdrawal cohorts (n=67 and n=107) [1][15][16]. Animal EEG studies used 120 nmol/kg subcutaneously in cats [13]. Mechanistic GH studies used 5 mcg intracerebroventricularly in rats [7]. The mouse aging and anti-tumor study used 2.5 mcg/mouse (~100 mcg/kg) subcutaneously for five consecutive days monthly [25].
None of the research protocols for this unnapproved research peptide translate to human dosing recommendations. The DSIP peptide dosage findings below are research-context descriptions only.
DSIP Peptide Dosing Chart: Research Protocol Ranges
The following table summarizes published research protocols by species, route, dose, and study objective. All entries are from peer-reviewed publications as listed in the DSIP dosing chart and referenced below.
| Species | Route | Dose | Duration | Study objective | Citation |
|---|---|---|---|---|---|
| Human | IV | 25 nmol/kg | 3 consecutive nights | Chronic insomnia (n=16) | Bes 1992 [1] |
| Human | IV | Not specified | 7 consecutive nights | Severe chronic insomnia (n=14) | Schneider-Helmert 1987 [3] |
| Human | IV | Not specified | 10 injections | Severe insomnia (n=7) | Kaeser 1984 [4] |
| Human | IV | Not specified | 1 acute dose | Insomnia (n=6) | Schneider-Helmert 1981 [2] |
| Human | IV | 25 nmol/kg | Multiple injections | Opiate/alcohol withdrawal (n=67) | Dick 1983 [15] |
| Human | IV | Multiple | Multiple injections | Withdrawal (n=107) | Dick 1984 [16] |
| Human | IV | 5 days + follow-up | Every 48-72 h | Chronic pain (n=7) | Larbig 1984 [18] |
| Cat | SC | 120 nmol/kg | Single dose | EEG/sleep architecture | Susic 1987 [13] |
| Rat | ICV | 5 mcg | Single dose | GH secretion mechanism | Iyer 1987 [7] |
| Rat | IP/IV | Not specified | Multiple | EEG power spectrum | Stanojlovic 2000 [14] |
| Rat | Intranasal | 120 mcg/kg | 8 days | Stroke motor recovery | Tukhovskaya 2021 [28] |
| Mouse | SC | ~100 mcg/kg | 5 days/month | Aging and tumor incidence | Popovich 2003 [25] |
DSIP half-life and plasma binding
Free DSIP plasma half-life is 2-4 minutes across mammalian species. Kato et al. (1984) measured a mean half-life of 4.0 +/- 0.7 minutes in dogs, 2.9 minutes in monkeys, and 2.0 +/- 0.54 minutes in rats using an enzyme immunoassay [11]. Metabolic clearance rate in dogs averaged 30.7 +/- 2.5 mL/kg/min.
Despite this rapid plasma clearance, in-vivo effects in published studies persist for hours to days. Two mechanisms are proposed: (1) carrier protein binding substantially extends DSIP's biological persistence in plasma relative to free-peptide half-life; (2) DSIP initiates downstream neuroendocrine cascades — GH pulse, pineal melatonin release, LH secretion — that outlast the peptide itself.
Endogenous DSIP is found in humans as the phosphorylated form DSIP-P, which resists aminopeptidase degradation and is more potent than the unphosphorylated nonapeptide in some assays [23]. In vitro half-life for unphosphorylated DSIP is approximately 15 minutes due to aminopeptidase activity.
U-shaped dose-response: what the research shows
DSIP demonstrates a parabolic (U-shaped) dose-response: minimal effective dose approximately 10 ng; maximal response at approximately 1 mcg in some assays; higher doses produce diminishing or no effect [23]. This is a non-linear pharmacological relationship seen in other neuropeptides and implies a narrow optimal dose window for research protocols.
The structural requirements are strict: analogs with exchanged or truncated amino acids show markedly reduced or abolished activity [23]. Phosphorylated DSIP-P is more potent than the native sequence. These structural constraints make dose-response data from one analog or route difficult to extrapolate to another.
How long does it take for DSIP to work?
In the Schneider-Helmert (1981) acute IV study, sleep benefit was observed beginning in the second hour post-injection in six chronic insomniacs [2]. In the seven-night Schneider-Helmert (1987) trial, benefit appeared from the first treatment night [3]. The Bes et al. (1992) trial measured aggregate effects across three nights rather than single-night onset.
Animal EEG data (rats) show increased delta activity measurable from hours 2 through 11 post-administration [14]. For daytime administration, the circadian-entrainment model implies benefit may appear in the following night's sleep rather than acutely — consistent with the Schneider-Helmert 1981 observation that a daytime dose improved the subsequent night [2].
DSIP Nasal Spray vs. Subcutaneous Injection: Administration Routes
Published human clinical trials have used intravenous administration exclusively. The subcutaneous route is documented in the cat EEG study (120 nmol/kg SC, Susic 1987) and the mouse aging study (~100 mcg/kg SC monthly, Popovich 2003) [13][25]. The nasal spray vs. subcutaneous injection comparison is an active research question rather than a settled one.
Intranasal DSIP has been used in rat stroke models: 120 mcg/kg intranasally over 8 days after focal stroke (Tukhovskaya 2021) significantly improved motor performance recovery vs. vehicle [28]. CNS penetration data from the Banks et al. (1986) dog study showed that plasma concentration, plasma half-life, and lipophilicity together predicted CSF entry (r = 0.813, p < 0.00005), providing the pharmacokinetic rationale for intranasal delivery as a route targeting direct CNS access [12].
The 2024 Frontiers in Pharmacology fusion-peptide study used a recombinant DSIP-BBB-crossing peptide expressed in yeast — an engineered approach to the same CNS-delivery problem [26]. Comparative bioavailability data across intranasal, subcutaneous, and IV routes in the same model have not been published.
Clinical research has not compared intranasal vs. IV DSIP directly. Based on available data, IV remains the only route with controlled human efficacy data.
DSIP injection frequency in research protocols
Published protocols vary: three consecutive nightly injections (Bes 1992) [1]; seven consecutive nightly injections (Schneider-Helmert 1987) [3]; ten injections over several weeks (Kaeser 1984) [4]; five consecutive daily doses followed by injections every 48-72 hours for pain management (Larbig 1984) [18]; multiple injections over the treatment course for withdrawal (Dick 1983, 1984) [15][16]; monthly five-day courses for aging/anti-tumor work in mice (Popovich 2003) [25].
No optimal frequency has been established. The U-shaped dose-response complicates dose-frequency generalisation: repeat-dose accumulation may shift the effective range, and the buildup effects noted in some trials may reflect receptor saturation or downstream cascade persistence rather than classical pharmacokinetic accumulation.
Timing of DSIP administration: day vs. night
Human insomnia trials administered DSIP intravenously before bedtime, consistent with the conventional model of a sleep-supportive compound. Schneider-Helmert (1981), however, documented that a daytime IV dose improved the following night's sleep, not the day-of-dose sleep period [2]. This observation is consistent with a circadian rhythm-entraining mechanism: endogenous DSIP peaks in the afternoon (approximately 15:00) and falls during the sleep period [21], and exogenous administration may reinforce this oscillation rather than acutely inducing sedation.
The practical implication for research protocol design is that administration timing may influence both the timing and magnitude of observed effects — and that interpreting single-night studies without accounting for circadian context may introduce variability.